- Home
- LCTX vs CSBR Comparison
LCTX vs CSBR Comparison
Compare LCTX & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- CSBR
- Stock Information
- Founded
- LCTX 1990
- CSBR 1985
- Country
- LCTX United States
- CSBR United States
- Employees
- LCTX N/A
- CSBR N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- CSBR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LCTX Health Care
- CSBR Health Care
- Exchange
- LCTX Nasdaq
- CSBR Nasdaq
- Market Cap
- LCTX 107.3M
- CSBR 113.0M
- IPO Year
- LCTX N/A
- CSBR 1986
- Fundamental
- Price
- LCTX $0.70
- CSBR $6.27
- Analyst Decision
- LCTX Strong Buy
- CSBR Strong Buy
- Analyst Count
- LCTX 5
- CSBR 1
- Target Price
- LCTX $4.20
- CSBR $12.00
- AVG Volume (30 Days)
- LCTX 1.5M
- CSBR 18.7K
- Earning Date
- LCTX 08-07-2025
- CSBR 07-17-2025
- Dividend Yield
- LCTX N/A
- CSBR N/A
- EPS Growth
- LCTX N/A
- CSBR N/A
- EPS
- LCTX N/A
- CSBR 0.46
- Revenue
- LCTX $9,557,000.00
- CSBR $58,591,000.00
- Revenue This Year
- LCTX N/A
- CSBR $15.11
- Revenue Next Year
- LCTX $232.66
- CSBR $7.80
- P/E Ratio
- LCTX N/A
- CSBR $13.92
- Revenue Growth
- LCTX 19.42
- CSBR 19.03
- 52 Week Low
- LCTX $0.37
- CSBR $3.60
- 52 Week High
- LCTX $1.15
- CSBR $11.99
- Technical
- Relative Strength Index (RSI)
- LCTX 62.72
- CSBR 46.94
- Support Level
- LCTX $0.48
- CSBR $6.17
- Resistance Level
- LCTX $0.83
- CSBR $7.10
- Average True Range (ATR)
- LCTX 0.06
- CSBR 0.39
- MACD
- LCTX 0.01
- CSBR 0.12
- Stochastic Oscillator
- LCTX 60.76
- CSBR 45.03
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About CSBR Champions Oncology Inc.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.